RDA Financial Network Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

RDA Financial Network lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 32.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,017 shares of the pharmaceutical company’s stock after selling 2,375 shares during the period. RDA Financial Network’s holdings in Vertex Pharmaceuticals were worth $2,020,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its stake in Vertex Pharmaceuticals by 0.8% during the third quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock worth $5,495,501,000 after acquiring an additional 90,173 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 18.1% during the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock valued at $2,581,373,000 after purchasing an additional 851,054 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Vertex Pharmaceuticals by 17.2% during the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock valued at $2,231,858,000 after purchasing an additional 704,421 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Vertex Pharmaceuticals by 5.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock worth $1,351,385,000 after purchasing an additional 159,693 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Vertex Pharmaceuticals by 4.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock worth $1,170,506,000 after buying an additional 100,114 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on VRTX. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Canaccord Genuity Group lifted their price target on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Monday. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Finally, Citigroup initiated coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 target price on the stock. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $490.38.

Vertex Pharmaceuticals Trading Down 1.7 %

Shares of VRTX opened at $416.96 on Friday. The business has a 50-day simple moving average of $444.54 and a two-hundred day simple moving average of $466.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period in the prior year, the firm posted $3.67 EPS. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post -1.9 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.